Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Tissue Regenix appoints new chief financial officer

The AIM-listed firm said Jones will join the group as CFO, company secretary and as an executive director on board on 30 November 2018

Tissue Regenix Group PLC (LON:TRX) has announced the appointment of Gareth Hywel Jones as chief financial officer.

The AIM-listed firm said Jones will join the group as CFO, company secretary and as an executive director on board on 30 November 2018.

WATCH: Tissue Regenix building its capabilities for future sustainable delivery

The medical devices company said Jones, who will join the group from Applied Graphene Materials PLC (LON:AGM), is an experienced CFO, bringing significant operational, high technology manufacturing and strategic financial expertise gained through roles in UK and US listed businesses as well as private equity.

Tissue Regenix added that current interim CFO, Paul Below, will remain with the group to facilitate an orderly hand-over.

Steve Couldwell, CEO Tissue Regenix, said: "After an extensive recruitment process, Gareth's proven experience of implementing operational enhancements, divisional business unit management, profit improvement initiatives and strategic commercial planning, in both UK and US quoted companies, will significantly strengthen our leadership team.“

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK